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Abstract
Background and Methodology: Toxoplasma gondii causes substantial morbidity, mortality, and costs for healthcare in the
developed and developing world. Current medicines are not well tolerated and cause hypersensitivity reactions. The
dihydrotriazine JPC-2067-B (4, 6-diamino-1, 2-dihydro-2, 2-dimethyl-1-(39(2-chloro-, 4-trifluoromethoxyphenoxy)propyloxy)-
1, 3, 5-triazine), which inhibits dihydrofolate reductase (DHFR), is highly effective against Plasmodium falciparum,
Plasmodium vivax, and apicomplexans related to T. gondii. JPC-2067-B is the primary metabolite of the orally active
biguanide JPC-2056 1-(39-(2-chloro-4-trifluoromethoxyphenyloxy)propyl oxy)- 5-isopropylbiguanide, which is being
advanced to clinical trials for malaria. Efficacy of the prodrug JPC-2056 and the active metabolite JPC-2067-B against T.
gondii and T. gondii DHFR as well as toxicity toward mammalian cells were tested.
Principal Findings and Conclusions: Herein, we found that JPC-2067-B is highly effective against T. gondii. We demonstrate
that JPC-2067-B inhibits T. gondii growth in culture (IC50 20 nM), inhibits the purified enzyme (IC50 6.5 nM), is more
efficacious than pyrimethamine, and is cidal in vitro. JPC-2067-B administered parenterally and the orally administered pro-
drug (JPC-2056) are also effective against T. gondii tachyzoites in vivo. A molecular model of T. gondii DHFR-TS complexed
with JPC-2067-B was developed. We found that the three main parasite clonal types and isolates from South and Central
America, the United States, Canada, China, and Sri Lanka have the same amino acid sequences preserving key binding sites
for the triazine.
Significance: JPC-2056/JPC-2067-B have potential to be more effective and possibly less toxic treatments for toxoplasmosis
than currently available medicines.
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Toxoplasmosis is a neglected tropical disease as well as a
significant illness affecting persons throughout the world and new
and improved medicines are greatly needed for this and other
apicomplexan infections [1–40]. In developing tropical countries,
the problems for persons with AIDS can be exacerbated due to
lack of both anti-retroviral treatment and anti-Toxoplasma gondii
treatment. In this setting, this opportunistic pathogen causes
substantial neurologic disease and treatment of this illness can be
especially difficult because current gold standard medicines are
unobtainable and/or unaffordable and, due to their toxicity,
require monitoring which exceeds the capacity of many of the
available health care systems. Toxoplasmic eye disease (chorioret-
initis) is frequent in certain areas of Brazil and Colombia, areas
where the gold standard drugs are particularly problematic, and is
caused by atypical parasites that present major recrudescent and
recurrent clinical problems. T. gondii is highly pathogenic and
lethal in an emerging problem in French Guiana and Suriname
[22,34].
Throughout the world, new T. gondii infection during pregnancy
can lead to devastating disease for the fetus and newborn infant,
later impacting on the child’s health and development and
potentially on his/her later productivity [1–3]. In all areas of the
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world, this infection is life threatening and causes substantial
neurologic damage for those with immune compromise. For some
immunologically normal individuals this infection causes recurrent
ophthalmologic and other organ damage [1–3].
Thus, toxoplasmosis is an important neglected disease in
developing tropical countries, as well as an important cause of
illness in developed countries in tropical and temperate climates
[16–37]. All forms of toxoplasmosis (acute acquired, with or
without symptoms; congenital; ocular; and in immune-compro-
mised persons) occur throughout the world [1–3,16–40]. In
Europe and in the U.S. reports are that there are three
predominant clonal types of T. gondii [22–24]. Clonal genetic
type II T. gondii have been reported to predominate in France,
Poland, and the U.S [24]. Atypical genetic types of T. gondii have
been reported to occur in association with unusually severe eye
disease in the U.S. in a small case series [25] and clonal type I
parasites in some patients with AIDS and toxoplasmic encephalitis
[26], but clonal type II parasites have been predominant among
U.S. and European human isolates reported to date [24].
The presence of atypical T. gondii parasites in South and Central
America have recently been discovered and found to be associated
with significant human disease [27–32]. T. gondii strains in certain
areas of Brazil, Colombia, and Guatemala [33] are atypical (rather
than the European and U.S. predominant three clonal types) and
are often genetically polymorphic [34]. In the Minas Girais area of
Brazil (36), infection with T. gondii is common. In Erechim, Rio
Grande do Sul 17.7% of the population had ocular toxoplasmosis.
In Colombia, where atypical, non clonal type I, II, or III, parasites
are endemic, frequency of retinal lesions of ocular toxoplasmosis in
medical residents was 6% [31]. Severe congenital disease occurs in
0.5% of live births in Colombia [32]. In addition, in sharp contrast
to clonal type II parasites predominating in Europe, in certain
tropical countries with wild felids and a wide variety of wild
mammals, the parasites are genetically more diverse and the many
potential mammalian hosts apparently appear to be associated
with the presence of greater genetic diversity in these atypical
strains [34]. For example, in French Guiana [34], parasites have
many felid hosts and these parasites have been considered to be
representative of those found in the tropical Amazon reservoir
[35]. In Northern Coastal South America they have caused lethal
and severe diseases in humans including French soldiers; these
diseases have included persistent neurologic findings, Guillain
Barre syndrome, severe pneumonia, and death [37].
Substantial waterborne epidemics have occurred in Brazil [38],
in Canada [39], and in U.S. soldiers in Panama [40], considered
to be secondary to feral or wild cats in proximity to drinking water
[38–40]. A cat excretes up to 20 million unsporulated oocysts
during just a few days, these become infections following
sporulation, and even 1 oocyst is infectious [1]. Oocysts excreted
by cats can persist in warm moist soil for up to a year and in
seawater for up to 6 months. Thus infection is readily spread in
nature and is a very common infection throughout the world.
Congenital toxoplasmosis is a significant problem in the
developed and developing world, but it is particularly difficult in
parts of the developing world to obtain the gold standard
medicines, pyrimethamine and sulfadiazine. For example, in
Colombia, it is not possible to obtain pyrimethamine and
sulfadiazine to treat congenitally infected infants. The cost of
compounding, administering and monitoring the safe use of these
medicines also would likely be prohibitive for most residents of
rural Africa or Central and South America.
These issues also are especially problematic for those with AIDS
and toxoplasmosis in the developing world, because the medicines
and the monitoring required for their proper and safe use are often
also both unavailable and unaffordable [17]. In patients with
AIDS, toxoplasmosis is a major, presenting, opportunistic, central
nervous system infection and this is also the case throughout the
entire course of the AIDS infection when HAART is not
obtainable or affordable [17]. Early in the AIDS epidemic in the
U.S. and Europe, approximately half of seropositive, i.e.,
individuals with chronic T. gondii infection, and AIDS infected
individuals developed toxoplasmic encephalitis [16]. An example
of the likely magnitude of this problem can be seen when one
considers sub-Saharan Africa [17]. In sub-Saharan Africa
approximately 25 million people have HIV infection/AIDS [18],
and co-infection with T. gondii frequently remains undetected and
thus untreated [17]. T. gondii seroprevalence ranges from 35% to
84% in different African countries south of Sahara (reviewed in
[19]). Because approximately 30–50% of persons who have been
co-infected with HIV and T. gondii in the U.S. or Europe in the
pre-HAART era ultimately developed toxoplasmosis, the high
seroprevalence in sub-Saharan Africa combined with the HIV-
pandemic indicate that 2.5–10 million people in this region are
likely to be at risk of dying from toxoplasmosis. A recent study of
types of parasites using a SAG2 marker indicated that all three
SAG2-types have been found in chickens in Africa [20].
HIV infection is not the only immunodepressive health
condition that is frequent in the developing world and that
worsens manifestations of toxoplasmosis. In India, adults who were
malnourished but otherwise immunologically normal and who
were without HIV infection had severe, symptomatic toxoplasmic
encephalitis [21].
Ideal medicines to treat toxoplasmosis in developing tropical
countries would be effective, easily obtained and affordable,
without toxicity, including hypersensitivity and neutropenia which
requires co-adminstration of leukovorin and careful monitoring of
neutrophil count. They also would be non teratogenic so the fetus
and pregnant woman could be treated. In addition they would be
rapidly effective, safe, without any toxicity, when available in
pediatric suspensions. Further, they would be available parenter-
ally for those who are acutely ill and unable to take oral medicines.
They would be effective against all isolates of T. gondii (all three
clonal types and atypical parasites). Ideally a medicine would also
be cidal against bradyzoites. An ideal medicine for toxoplasmosis
Author Summary
Toxoplasmosis is a neglected tropical disease, an emerging
disease as well as a significant problem in developed
countries causing a substantial health burden. Better
medicines with less toxicity are greatly needed. Herein,
we found that a novel triazine currently being advanced to
clinical trials for malaria, JPC-2067-B, is highly effective
against T. gondii. We demonstrate that JPC-2067-B inhibits
T. gondii growth in culture (IC50 20 nM), inhibits the
purified enzyme (IC50 6.5 nM), is more efficacious than
pyrimethamine, and is cidal in vitro. JPC-2067-B adminis-
tered parenterally and the orally administered pro-drug
(JPC-2056) are also effective against T. gondii tachyzoites in
vivo. A molecular model of T. gondii DHFR-TS complexed
with JPC-2067-B was developed. We found that the three
main parasite clonal types and isolates from South and
Central America, the United States, Canada, China, and Sri
Lanka have the same amino acid sequences preserving key
binding sites for the triazine. Toxicology data are
presented. JPC-2056/JPC-2067-B have potential to be
more effective and less toxic treatments for toxoplasmosis
than currently available medicines.
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would have superb penetration into the eye and brain. These
would be major advantages for this neglected disease throughout the
world, and especially important in developing countries. JPC-2056/
JPC-2067-B have the potential to address some of these issues (e.g.
cidal for tachyzoites, less toxicity, available for oral and parenteral
use, and potentially available in pediatric suspensions that are stable
without refrigeration). Further testing and development will reveal
whether JPC-2056/JPC-2067-B can address the other characteris-
tics of an ideal anti-toxoplasmosis medicine.
Current treatment of toxoplasmosis includes the combination of
a folic acid antagonist and an inhibitor of dihydropteroic acid
synthesis: The gold standard treatment has been the classic anti-
malarial combination of pyrimethamine and sulfadiazine. In vitro
and in vivo experimental models of toxoplasmosis parallel this
clinical approach [1,3]. Herein, results using those same in vitro and
in vivo toxoplasmosis models with a new anti-malarial candidate,
JPC-2067B (4, 6-diamino-1, 2-dihydro-2, 2-dimethyl-1-(39-(2-
chloro-4-trifluoromethoxyphenoxy) propyloxy)-1, 3, 5-triazine)
and its pro-drug JPC-2056 are presented [4–10]. This new anti-
malarial class [4–10], without a sulfonamide, has dramatic potency
against multi-drug resistant Plasmodium falciparum strains [4–10].
We have waited a long time for a representative of this series of
compounds to advance to the clinic for the treatment of T. gondii
infection. This is especially important for those with this infection who
are immune compromised and potentially also for those infected in
pregnancy and in utero. New medications are needed because the
classic gold standard medications have substantial toxicity [1,2].
Moreover, pyrimethamine cannot be used in the first trimester of
pregnancy, as folate depletion is detrimental to fetal development [1].
Neutropenia is a common toxicity with pyrimethamine treatment
even when leukovorin is administered in conjunction with this
medicine [3]. Furthermore, pyrimethamine is generally administered
in a synergistic combination with sulfadiazine which has substantial
associated hypersensitivity [2] and toxicity (e.g. kidney stones or
hepatic or renal complications). New medicines are greatly needed for
individuals suffering from toxoplasmosis
The extremely promising candidate, JPC-2067-B, comes from a
pre-clinical anti-malarial series well known in malariology by the
name of the related metabolite WR99210 (4,6-diamino-1,2-
dihydro-2,2-dimethyl-1-[39(2,4, 5-trichlorophenoxy)propyloxy]-1,
3, 5-triazine) [4–10]. In vitro anti-malarial testing of WR99210
against drug-sensitive and drug-resistant strains has shown high
potency and full activity against P. falciparum strains not responsive
to pyrimethamine, proguanil or chloroquine with an ED50 of
0.05 ng/mL in vitro. As yet there is no strain resistant to this class of
compounds. WR99210 is discussed here in order to provide a
common point of cross reference. Like proguanil, the new clinical
candidate JPC-2056 (Figure 1) is a biguanide pro-drug which is
metabolized in vivo to the active dihydrotriazine JPC-2067-B
(Figure 1). For in vitro testing the metabolite must be used; for oral
usage the biguanide must be given. The ongoing work in
development and progression to use in the care of patients of
this very promising anti-malarial clinical candidate (Jacobus et al ,
unpublished) also is useful in development of the same medicine
for treatment of toxoplasmosis.
The previously described triazine WR99210 and its pro-drug,
PS-15, were developed in response to resistance of P. falciparum to
pyrimethamine and cycloguanil [4–11]. WR99210 was found to
be a very tight binding and potent inhibitor of P. falciparum DHFR-
TS [4–11]. WR99210 and PS-15 also were highly active in vivo
against P. falciparum, with activity 2 logs greater than that of
pyrimethamine. These compounds were also highly active against
P. vivax, without cross-resistance to other antifolates (S. Hunt,
personal communication). The therapeutic/toxic ratio is increased
because the high avidity of these compounds for the P. falciparum
DHFR differs from its lower avidity to mammalian DHFR [11].
Unfortunately, toxicity of WR99210 limited its development and
use and it will not be a clinically useful compound.
We previously evaluated the active triazine metabolite of
proguanil (cycloguanil) against T. gondii tachyzoites [12], and
more recently found that WR99210 was also highly active against
T. gondii in vitro and in vivo when administered parenterally [13].
PS15 also was found to be effective in vivo [13].
A major drug discovery effort over the past 6 years has
identified an analog of WR99210, JPC-2067-B, which has superior
pharmacological characteristics. Importantly, pro-drug JPC-2056,
is easily absorbed, bioavailable, and relatively nontoxic. In studies
with P. falciparum, oral administration of JPC-2056 resulted in
conversion to the JPC-2067-B which was cidal for the malaria
parasite. The high potency and selectivity of JPC-2067-B for
inhibition of apicomplexan parasite DHFR relative to mammalian
DHFR reduces the likelihood of neutropenia, thus enhancing the
margin of safety and convenience in monitoring white blood
counts with its use. JPC-2056 was also as active as monotherapy in
vitro as the synergistic combination of pyrimethamine and
sulfadiazine and is currently being advanced to clinical trials,
leading to a new and markedly improved class of anti-folate
medicines for the treatment of malaria.
The effect of JPC-2067-B on T. gondii is of considerable interest
and importance. The lack of toxicity of JPC-2067-B and the
favorable absorption and distribution profile of its prodrug JPC-2056
offers the possibility of overcoming the limitations of pyrimethamine.
The benefit of greater specificity for the parasite rather than host
DHFR could have the dual advantage of reducing host toxicity while
eliminating the need for simultaneous administration of a sulfon-
amide. Whether an IC 50 of 6.5 nM is sufficient to be used as a
single agent for either malaria or toxoplasmosis or would be better
used in conjunction with another anti-microbial in vivo under clinical
conditions remains to be determined.
Structures of JPC-2067-B and its corresponding pro-drug JPC-
2056 (Jacobus Pharmaceutical Company, Princeton, NJ) are
shown in Figure 1. The biguanide pro-drug is converted in vivo
to the biologically active dihydrotriazine through P450 metabolism
in the liver, and so in vitro experiments are always conducted with
the dihydrotriazine (JPC-2067-B). The overall aim of the
experiments was to determine effect of the dihydrotriazine on T.
Figure 1. Structures of triazines JPC-2056 and JPC-2067-B.
doi:10.1371/journal.pntd.0000190.g001
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gondii in vitro and in vivo and inhibitory effect of the dihydrotriazine
on T. gondii that was observed is described herein.
Methods
Parasites and assessment of effect of inhibitors on T.
gondii tachyzoites in tissue culture and cells in tissue
culture
Tachyzoites of the RH strain of T. gondii were passaged in
human foreskin fibroblasts (HFF). They were used to infect
fibroblasts to determine antimicrobial effects of candidate
compounds. Outcome was assessed with microscopy and uracil
uptake after four days in culture as described [8,12,13]. Briefly, for
testing of inhibitors in vitro against T. gondii tachyzoites, four-day
old confluent cultures of human foreskin fibroblasts (HFF) were
infected with 103 tachyzoites and cultured for 1 hour to allow
parasite invasion. Inhibitor was added and cells cultured for
3 days. They were supplemented with 3H uracil and incubation
extended for a further day, whereupon uracil incorporation into
cells and thus parasite growth were assessed by liquid scintillation
counting [8,12,13]. Studies were performed with inhibitors as
described in [8,12,13]. Lack of toxicity for mammalian host cells
was demonstrated first by visual inspection of the monolayer and
by parallel concomittant evaluation of separate 3H thymidine
incorporation assays by non-confluent HFF cell monolayers.
JPC-2067-B for use in in vitro (tissue culture) and in vivo
studies
For in vitro studies, a stock solution of JPC-2067-B was initially
dissolved in 100% dimethyl sulfoxide (DMSO) and then diluted in
complete tissue culture medium (IMDM-C) [IMDM with
NaHCO3 and 25 mM Hepes (Cambrex Bio Science, Walkersville,
MD), 10% fetal bovine serum (Gibco, Grand Island, N.Y.), 16
antibiotic-antimycotic solution (Cellgro, Mediatech), and 2 mM L-
glutamine (Gibco). Working concentrations of JPC-2067-B were
made using IMDM-C. Concentrations measured ranged from 10
to 100 nM. For certain in vivo studies, JPC-2067-B was initially
dissolved in 100% DMSO and then diluted 100 fold in 16 PBS
without calcium or magnesium (Cellgro) and administered intra-
peritoneally (i.p.) 15 minutes following i.p. inoculation of the
parasite. In other in vivo studies, the orally bioavailable pro-drug
JPC-2056 (40 mg/kg/dose, bid) was administered per orally by
gavage beginning one day following i.p. inoculation of the parasite.
DHFR enzyme activity and its inhibition by JPC-2067-B:
Effect against T. gondii DHFR compared to Pneumocystis
carinii, Mycobacterium avium-intracellulare and rat liver
DHFRs
DHFR from Pneumocystis carinii was produced as the recombinant
enzyme expressed in Escherichia coli [41]. The sequence of the protein
was identical to that predicted for the previously reported gene
sequence [4]. DHFR from T. gondii was isolated directly from RH
strain T. gondii grown in culture on Chinese hamster ovary cells
lacking DHFR (CHO/dhfr-, American Type Culture Collection
3952 CL) [42]. Organisms were introduced into a confluent
monolayer and harvested when the mammalian cells were lysed.
The 100,0006g supernate was stored in liquid nitrogen.
Mycobacterium avium-intracellulare used in these studies was a
clinical isolate (serovar 4) from Indiana University School of
Medicine, Department of Pathology. The strain was maintained
on Lowenstein-Jensen slants (Baxter Scientific) grown at room
temperature. To produce enzyme, the organism was grown in
Middlebrook 7H-9 liquid medium at 37uC to an OD660 of 0.5 to
0.7, which took several weeks. At harvest, the bacteria were
centrifuged, sonicated, and the 100,000 Xg supernate was stored
under liquid nitrogen until assay. These supernates contained both
DHFR and dihydroopteroate synthetase activity.
Rat liver DHFR was prepared from livers of female Sprague-
Dawley rats. The 100,0006 g supernate was partially purified by
ammonium sulfate precipitation; the 50–90% precipitate was re-
dissolved and stored in liquid nitrogen.
The spectrophotometric assay for DHFR was optimized for
temperature and concentration of substrate and cofactor for each
enzyme. The standard assay contained Na phosphate buffer pH 7.4
(40.7 mM), 2-mercaptoethanol (8.9 mM), NADPH (0.117 mM),
dihydrofolic acid (0.09 mM), KCL (150 mM), and sufficient enzyme
to produce a change in OD340 of 0.035/minute at 37uC. The
reaction was continuously recorded for 3 minutes. Activity under
these conditions was linear with enzyme concentration over a 4-fold
range. The low background activity in the absence of dihydrofolic
acid was subtracted from all rates.
DHFR was assayed with several concentrations of inhibitor to
produce rates ranging from 1 to 90% of the uninhibited rate. At
least three concentrations were required for calculation; most
curves contained five concentrations. Semi-logarithmic plots of the
data gave sigmoidal curves that were fit by non-linear methods to
determine the concentration yielding 50% inhibition (IC50) [Prism
4.0 (GraphPad)].
Effect against T. gondii DHFR compared with P.
falciparum DHFR and human DHFR
DHFR from T. gondii [43] prepared as above was also directly
compared to purified recombinant P. falciparum DHFR (pfDHFR)
and purified recombinant human DHFR (hDHFR). The hDHFR
was from pDFR plasmid [10]. The enzyme was purified following
ammonium sulfate precipitation, methotrexate:agarose affinity
chromatography, and finally a Superdex 200 size exclusion
column. The pfDHFR isolation methods were those reported
previously [11,44]. Pyrimethamine and JPC-2067-B were tested
for activity against recombinant pfDHFR, recombinant hDHFR
and the T. gondii lysate DHFR. The same buffer as used in the
other assays comparing T. gondii DHFR with DHFRs from rat
liver P. carinii and M. avium intracellulare was used but the maximal
activity, temperature, and length of observation were adjusted for
assays on the specific plate reader. The series of pfDHFR and
hDHFR assays were run twice for hDFHR and three times for
pfDHFR and the representative data are shown (see Results). The
tgDHFR sample was exhausted after one set of assays at a lower
activity than the others (uninhibited change in OD340 of 0.004/
min versus 0.02/min for the recombinant enzymes). The reaction
was setup at 23uC, the plate loaded, and the OD340 recorded at
20 second intervals for 10 minutes. The first 8 minutes were used
to generate linear fit slopes in Excel. Each concentration has been
reported as the mean of 5 replicate reactions with the standard
deviation reported as the error. Results are expressed as the
percent of control activity versus log concentration of inhibitor.
Prism 5.0 was used to generate curves from 12 different
concentrations of inhibitor using a non-linear fit method.
Quantitation of JPC-2067-B
JPC-2067-B levels were quantitated using an HPLC system
comprised of a Spectra System P4000 pump, AS300 autosampler,
UV2000 detector and a ChromJet integrator. The column is a
Phenomenex Synergi 4m MAX-RP 80A 15064.6 mm, s/n
219259. Elution was effected with a gradient of Mobile Phase A
(0.05% aqueous TFA) and Mobile Phase B (0.025% TFA in
acetonitrile). The flow rate was 0.5 ml/min, the injection volume
Novel Triazine JPC-2067-B Inhibits T. gondii
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was 20 ml and the detector was set to 290 nm. Observed retention
times for WR99210, PS-15 and JPC-2067-B were 9.5, 15.7 and
9.1 minutes, respectively.
T. gondii Infection of mice
Tachyzoites also were used to infect mice. Outbred Swiss
Webster mice were bred in our specific pathogen free colony.
When they were approximately 30 g, they received 10,000 RH
strain tachyzoites intra-peritoneally (i.p.); numbers of parasites
present in peritoneal fluid were counted four days later as
described [8,13]. Mice were maintained and utilized in accor-
dance with IACUC and NIH guidelines and approvals.
Studies of effect of peritoneal administration of JPC-
2067-B on murine toxoplasmosis
JPC-2067-B was administered parenterally. In initial studies,
this was given 15 minutes after i.p. infection and then each day for
four days(1.25 mg/kg/day). Peritoneal parasite burden was
quantitated on the fourth day after injection. Control mice
received 1% DMSO in PBS.
Studies of effect of oral administration of JPC-2056 on
murine toxoplasmosis
Beginning one day following infection of outbred SW mice with
tachyzoites of the RH strain of T. gondii mice received JPC-2056 by
gavage at a concentration of 40 mg/kg in 0.5 ml twice daily.
Peritoneal T. gondii burden was determined on day 4 following
infection.
PCR and bioinformatics of DHFR in various clonal and
atypical strains of T. gondii
Sequences of DHFR in each of the conventional parasite clonal
types (RH, type I; Me49 type II; and VEG, type III) from the data
base and by PCR using strains (isolates) from Brazil, Guyana,
Guatemala, Canada, China, and Sri Lanka [45–50] were deter-
mined with PCR using cDNA or g DNA as template. The primers
used were: Forward, 59-AGGGACGGTGAAGTTTCGCTTTA-
39; Reverse, 59-TTTCCGGTCTTCTTCGTCCATCCA-39.
Modeling of DHFR
Modeling of the T. gondii DHFR was based upon the crystal
structure of the closely related P. falciparum DHFR in complex with
WR99210, NADPH and dUMP (pdb id 1j3i), using the structure
based sequence alignment as a guide. Those residues which
displayed sequence variation between P. falciparum and T. gondii
DHFR and were located within 4A˚
´
of the ligand binding pocket
were analysed to look for significant differences.
Toxicology studies
A 42-day toxicology study in CD-1 mice at doses up to 98 mg/
kg evaluating well-being, weight gain, and histopathology was
performed. A comparable 42-day toxicology study in Macaca
fascicularis also was performed. 7.5 mg/kg was established as the
NOAEL (No Observed Adverse Effect Level). JPC-2056 and JPC-
2067 were assayed in the Ames Test with and without microsomal
activation with tester strains TA97, TA98, TA100, TA102 and
TA1535.
Statistical analysis
Significance of differences was determined using a Mann Whitney
U test or Student’s T-test. All experiments were performed at least
twice and representative experiments are shown.
Results
Effect of JPC-2067-B on T. gondii tachyzoites in vitro
JPC-2067-B was highly effective against T. gondii tachyzoites in
tissue culture. A representative experiment of two trials is shown in
Figures 2A and B. The IC50 and IC90 for JPC-2067-B were
<20 nM and 50 nM, respectively. Differences between control and
treated groups at these and higher concentrations were statistically
significant (p,0.05). We observed some precipitation of the
compounds in the stock solutions, and so the supernatant was
analyzed by HPLC. We found that the actual concentrations
measured in the supernatants were approximately four-fold less than
the initial amounts. The actual amounts measured are shown in
Figure 2. Data are shown both as uptake of 3H uracil into nucleic
acid of the parasites (Figure 2B) and with micrographs of Giemsa
stained microscopic preparations (Figure 2C), with efficacy con-
firmed by both methods. Direct comparison of WR99210 and JPC-
2067-B and similar IC 50 and 90s for WR99210.
Lack of toxicity of JPC-2067-B for human fibroblasts
tested concomitantly with T. gondii tachyzoites
Human foreskin fibroblasts were tested concomitantly with T.
gondii tachyzoites with increasing concentrations of JPC-2067-B.
Data from a representative experiment are also shown in Figure 2A
and demonstrate no toxicity measured as uptaked of tritiated
thymidine by nonconfluent fibroblasts. The increased uptake of
thymidine in these cultures remains unexplained but also has been
noted with certain other compounds such as triclosan.
JPC-2067-B is cidal for T. gondii
In separate experiments, to determine whether JPC-2067-B would
be cidal for T. gondii, cultures were maintained for 52 days after
removing JPC-2067-B on the 4th day of culture. No plaques or growth
of parasites were detected (Figure 2D). The absence of growth follow-
ing removal of JPC-2067-B from HFF exposed to T. gondii indicates
that this compound is ‘‘cidal’’ and not merely ‘‘static’’ for T. gondii.
In vivo effect of parenteral administration of JPC-2067-B
and oral administration of the pro-drug JPC-2056 on
toxoplasmosis
JPC-2067-B was also highly effective against T. gondii tachy-
zoites in a mouse model. A representative experiment with JPC-
2067-B is shown in Figure 3A. In the experiment in Figure 3A,
mice were infected i.p. with 10,000 tachyzoites of the RH strain of
T. gondii for 15 minutes prior to initial treatment with JPC-2067-B.
For these parenterally treated mice, female mice received a dose of
1.25 mg/kg/day of JPC-2067-B, administered i.p. for the next
3 days. Control mice received an equivalent amount of DMSO (1%)
in 16PBS. In a separate experiment, DMSO at this concentration
was shown not to modify subsequent parasite numbers when
compared with i.p. inoculation of PBS. Mice treated with JPC-2067-
B appeared sleek and active 4 days after infection. In contrast,
infected control mice appeared ill, with ruffled fur and hunched
posture. Intraperitoneal parasite numbers were reduced by two logs
with treatment with JPC-2067-B on the fifth day after injection of
parasites (Figure 3A). These differences between control and treated
mice were statistically significant (p,0.05).
In addition, a similar experiment was performed with oral adminis-
tration of the orally bioavailable pro-drug JPC-2056 (40 mg/kg/
dose, bid) beginning one day following i.p. inoculation of the parasite.
Parasite number in peritoneal fluid was quantitated three days after
that, i.e. the fourth day following infection. For the mice orally treated
with JPC-2056 there were similar significant differences in parasite
peritoneal burden on the third day of treatment (Figure 3B, p,0.03).
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Figure 2. Effect of JPC-2067-B on T. gondii in human foreskin fibroblasts. A. Thymidine uptake assay demonstrates no toxic effect on host
cells. B. Uracil uptake assay demonstrates that JPC-2067-B is effective against T. gondii at low nanomolar concentrations. C. Micrographs showing
marked inhibition of T. gondii by JPC-2067-B. Note absence of plaques and parasites in treated cultures. Concentrations prepared are shown. D.
Micrograph showing absence of destruction of monolayers infected, exposed to JPC-2067-B for 4 days and cultured for prolonged times with T.
gondii. The control monolayer was completely destroyed by 5 days of culture. This contrasts with similarly infected monolayers in the micrograph
exposed to JPC-2067-B for 4 days and then with the JPC-2067-B removed. No plaques or Toxoplasma were seen throughout 52 days of culture,
demonstrating that the JPC-2067-B is cidal and no drug resistant mutants were selected in this experiment. No plaques were present from 4 days
through the subsequent 1 and 1/2 months after in vitro challenge.
doi:10.1371/journal.pntd.0000190.g002
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Effect of JPC-2067-B on T. gondii DHFR enzyme activity
compared with effects on DHFR enzyme activity from
mammalian cells, Pneumocystis carinii, and
Mycobacterium avium-intracellulare
The IC50 values determined for reference compound pyrimeth-
amine (JPC-1090) were in agreement with prior assays of the
compound (S. Queener, unpublished data). Both JPC-1090 and
JPC-2013 (cycloguanil) had IC50 values in the micromolar range
and were not significantly selective for pathogen DHFR (Table 1).
JPC-208 (WR92210) was more potent, with IC50 values in the
nanomolar range, but was not selective. JPC-2067-B had nanomolar
IC50 values for the DHFRs from all three pathogens and higher
IC50 value for the mammalian DHFR, yielding about 3.4 to 5.9 fold
selectivity. The potency for this compound greatly exceeds the
concentration of pyrimethamine used clinically (Figure 4).
Semilogarithmic plots of the data yielded normal sigmoidal
curves for pyrimethamine and cycloguanil (Hill slope of the
Figure 3. Reduction of numbers of parasites in peritoneal fluid. A. Reduction of numbers by i.p. treatment of mice with JPC-2067-B. B.
Reduction of numbers of parasites following treatment of mice with the pro-drug JPC-2056. JPC-2056 was administered by gavage. JPC-2056 is
converted into the active compound, JPC-2067-B.
doi:10.1371/journal.pntd.0000190.g003
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normalized log-concentration-response curve was about 21) but
both WR-99210 and JPC-2067-B yielded very steep curves for the
DHFRs from rat liver, P. carinii, and T. gondii; these compounds
produced normal dose response curves with M. avium DHFR. The
steep Hill slopes for JPC-208 and JPC-2067-B suggests that the
interaction of these compounds with these enzymes is not following a
simple 1:1 interaction expected with a competitive inhibitor.
Effect of JPC-2067-B on T. gondii DHFR enzyme activity
compared with effect on P. falciparum and human DHFR
enzyme activities
In Figure 5 and Table 2, the IC50 for P. falciparum DHFR was
3.9 nM, T. gondii DHFR was 32 nM, and human DHFR was
150 nM. For pyrimethamine, the IC50 for P. falciparum was 42 nM,
for T. gondii DHFR was 280 nM, and for human DHFR was
1,900 nM.
The differences in values between Figures 4 and 5 may be due to
variations in assays. Assays towards the comparison to inhibition of
opportunistic pathogens are run on partially purified lysates at 37uC
for a shorter duration while this set of assays is run in a high-
throughput manner with several recombinant enzymes and a more
drawn out observation time at 23uC. The amount of enzyme used
has been reduced to extend the length of observation and minimize
the effect of data points lost during plate setup. These differences in
methodology likely explain the slight shift in IC50. The ratio of IC50
values measured via high throughput method (hDHFR/tgDHFR) to
the ratio measured from lysates (rat liver DHFR/TgDHFR) under
different conditions are 4.6 versus 3.4, which are comparable.
Overall, JPC-2067-B has considerable potency and some
selectivity relative to mammalian reference enzymes, in two
independent laboratories under slightly different assay conditions
demonstrating the effect of this compound on T. gondii DHFR.
Molecular modeling of T. gondii DHFR [51] and
JPC-2067-B
In order to further investigate the efficacy of the dihydrotria-
zines on P. falciparum versus T. gondii with regard to drug design
and molecular mode of action, we have analyzed structural models
of the DHFR enzyme in the apicomplexan parasites. Of the 9
residues which form interactions with the dihydrotriazine
inhibitor, WR99210 in the structure of P. falciparum DHFR
Ile14, Cys15, Asp54, Met55, Phe58, Ile111, Leu119, Ile164 and
Tyr170 all are either identical or very similar in T. gondii DHFR
(Figure 6A). In particular Asp54 and Tyr170 which make
important H-bonds to the inhibitor are conserved in T. gondii
DHFR. Furthermore, modeling studies suggest that the substitu-
tion of Ile in P. falciparum DHFR for Met and Val at positions 111
and 164, respectively, in T. gondii DHFR results in little change in
the Van der Waals packing interactions made to the inhibitor
(Figure 6B). Modeling of the potent inhibitor JPC-2067-B into T.
gondii DHFR reveals that the additional trifluoromethoxy group is
positioned such that it is exposed to the solvent and as such can
probably be tolerated by the enzyme with respect to inhibitor
Table 1. Comparison of IC50 of JPC-2067-B against DHFRs of T. gondii and other opportunistic pathogens that are harmful to
patients with AIDS.
Compound Rat liver DHFR IC50 (mM) Pc DHFR IC50 (mM) Tg DHFR IC50 (mM) Mav DHFR IC50 (mM)
JPC-1090-A-1 (Pyrimethamine) 1.32 (1.14–1.55) 6.17 (5.45–6.98) 0.14 (0.12–0.16) 1.2 (0.93–1.45)
JPC-2013-B-1 1.73 (1.48–2.03) 8.9 (8.2–9.7) 0.41 (0.38–0.43) 12.1 (11.2–13.1)
JPC-208-B (WR99210) 0.00081 (0.0007–0.00093) 0.000265 (0.00025–0.00029) 0.000602(0.00057–0.00063) 0.00057 (0.00047–0.00071)
JPC-2067-B 0.0222 (0.0206–0.0238) 0.00393 (0.00371–0.00417) 0.0065 (0.00626–0.00674) 0.00375 (0.00291–0.00483)
Values shown are micromolar IC50 values (95% confidence limits).
doi:10.1371/journal.pntd.0000190.t001
Figure 4. Activity of pyrimethamine and JPC-2067-B against T.
gondii and rat liver DHFRs and DHFRs of other opportunistic
pathogens.
doi:10.1371/journal.pntd.0000190.g004
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binding. In addition, Cys50, which when mutated has been shown to
play a role in pyrimethamine resistance [52] in P. falciparum DHFR,
is replaced by His27 in T. gondii DHFR. Given its position close to
the trifluoromethoxy group of JPC-2067-B it may well be that
further modification to this part of the inhibitor could lead to
favorable interactions with the imidazole ring of His27 (Figure 6B).
However, these small changes in the T. gondii JPC-2067-B binding
site, when compared to its homologue in P. falciparum may contribute
to the somewhat lower sensitivity of this enzyme to JPC-2067-B.
DHFR sequences from clonal type I, II and III parasites
and atypical parasites including those found in
developing tropical countries
The deduced amino acid sequences of DHFRs [43] in the data
base for RH(U.S., type I), Me49 (U.S., type II), VEG (U.S., type
III), and Coug (atypical), and identified by PCR of DHFRs from
strains isolated from Brazil, Canada, Guyana, Guatemala, China
and Sri Lanka (Table 3, [45–50]) were identical (data not shown).
Figure 5. Activity of pyrimethamine and JPC-2067-B against T. gondii, P. falciparum, and human DHFRs.
doi:10.1371/journal.pntd.0000190.g005
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Toxicology studies
A 42-day toxicology study in CD-1 mice (Table 4) produced no
histopathology findings at doses up to 98 mg/kg and no gross
pathology with the exception of a reduction in the rate of weight
gain. A comparable 42-day toxicology study in Macaca fascicularis
(Table 4) produced histopathology findings at 15 mg/kg with
sproradic episodes of loose stools/diarrhea that resolved upon
drug withdrawal. No histopathology or gastrointestinal effects
were observed over the 42-day period. 7.5 mg/kg was established
as the NOAEL (No Observed Adverse Effect Level). When JPC-
2056 and JPC-2067 were assayed in the Ames Test, with and
without microsomal activation, no activity was exhibited with
tester strains TA97, TA98, TA100, TA102 and TA1535 (Table 4).
Discussion
Our studies demonstrate that JPC-2067-B is effective against T.
gondii in vitro with an IC50 of 20 nM and in vivo when administered
by i.p. injection and the pro-drug JPC-2056 is effective in vivo when
administered orally. Each of our results described herein with this
novel new class of anti-folate compound, dihydrotriazine, parallels
earlier findings with progenitors of this class which were not as
suitable for use for humans, e.g. proguanil [12] and WR99210
[13]. The major and compelling advantages of JPC-2056, which is
moving into clinical trials, is in the reduction of toxicity and
development of a much more readily bioavailable compound than
WR99210. WR99210 will never be a medicine for humans
because of difficulties in those areas, also reflected in the effect on
the mammalian enzyme, Table 1. The advantages of bioavail-
ability, high potency, specificity, selectivity and potential for
elimination of toxicities that occur with pyrimethamine either used
alone or in conjunction with sulfadiazine and other medicines and
because JPC-2056 will be entering clinical trials for the treatment
of malaria, testing of this new class of anti-folates against the
related apicomplexan T. gondii , was very important. Our results
suggest that the activity against T. gondii is significant and that JPC-
2056 has the potential to replace the combination of pyrimeth-
amine plus sulfadiazine or second line drugs in the treatment of
toxoplasmosis.
The modeling of T. gondii DHFR in complex with this family of
inhibitors gives us understanding at the molecular level of why
compounds of this class are highly active against T. gondii
tachyzoites. JPC-2056 already has been optimized for pharmaco-
kinetics and lack of toxicity and is being progressed to the clinic as
a potentially effective treatment for both P. falciparum and P. vivax
malaria. This ongoing work with malaria treatment provides a
major benefit for the development of JPC-2056 for the treatment
of toxoplasmosis.
It was of importance to determine whether in DHFR the amino
acids that bind this novel, highly active triazine vary in any of the
atypical parasites. Analysis of available DHFR sequences in the
data base for T. gondii isolates called RH, Me 49, VEG and Coug
parasites, i.e., from a clonal types I, II and III and atypical strains,
and analyses of isolates from Brazil, Guyana, Guatemala, Canada,
China, and Sri Lanka [45–50] demonstrates that the key amino
acids for binding the triazine are conserved (data not shown).
There are parasites that are genetically different in different
countries, e.g. in Brazil there are a variety of genetically different
parasites of clonal type I/III background with an association with
a very high prevalence of retinal disease; in Northern Coastal
South America highly virulent parasites that have recently been
lethal or caused severe illness and death in French soldiers in
French Guiana and in a recent epidemic in a village in Suriname
[53]; and atypical parasites in Central America and Mexico. In
Asia there are unique genotypes which differ from the typical I, II,
III genotypes, and in Africa there are all the genetic clonal types of
parasites. In Europe and Poland the predominant type is clonal
type II, and in the U.S. there are other types but a recent abstract
described predomininance of type II parasites. In an epidemic in
Sea Otters in Moro Bay California and on Vancouver Island, the
parasites are also atypical. Each of these parasites might have
different growth rates (new isolates often grow more slowly than
laboratory adapted strains, JP Dubey, personal observations) and
DHFRs with slightly different sequences or significant mutations
are a possibility. To begin to address this issue as it is relevant to
toxoplasmosis in the developing world, we have compared the
sequences of DHFRs in each of the conventional parasite clonal
types (I, II, and III) from the data base, and by PCR of DHFR
from isolates including a Brazilian strain, a strain from Guyana, a
strain from Guatemala, a strain from Canada, a strain from China
and a strain from Sri Lanka (Table 3; [45–50]). There are no
differences in amino acid sequence of the DHFRs.
As shown in the enzyme inhibition and parasite inhibition
assays herein, upon conversion of JPC-2056 to JPC-2067-B by
cytochrome p 450, the product, JPC-2067-B, becomes a highly
effective treatment for apicomplexan infections. Toxicological data
(Table 4) supports the advancement of JPC-2056 to clinical
development. A 42-day toxicology study in CD-1 mice produced
no histopathology finings at does up to 98 mg/kg and no gross
pathology with the exception of a reduction in the rate of weight
gain. A comparable 42-day toxicology study in Macaca fascicularis
produced histopathology findings at 15 mg/kg with sproratic
episodes of loose stools/diarrhea that resolved upon drug
withdrawal. Antimicrobial activities of JPC-2067 suggest that the
gastrointestinal events may be related to disruptions in intestinal
flora. No histopathology or gastrointestinal effects were observed
over the 42-day period. 7.5 mg/kg was established as the NOAEL
(No Observed Adverse Effect Level). JPC-2056 and JPC-2067
were assayed in the Ames Test with and without microsomal
activation. No activity was exhibited with tester strains TA97,
TA98, TA100, TA102 and TA1535. In summary, JPC-2056 has
two advantages over WR99210. Biguanides are better absorbed
and less toxic than their dihydrotriazine metabolites as has been
well established in the case of Proguanil. Cycloguanil, the active
dihydrotriazine metabolite of biguanide prodrug Proguanil is
Table 2. Comparison of IC50 of JPC-2067-B and Pyrimethamine against recombinant PfDHFR and hDHFR and DHFR activity of Tg
lysates.
Compound hDHFR IC50 (mM) PfDHFR IC50 (mM) TgDHFR IC50 (mM)
JPC-1090-A-1 (Pyrimethamine) 1.90 (1.77–2.05) 0.0422 (0.0369–0.0483) 0.275 (0.236–0.321)
JPC-2067-B 0.148 (0.136–0.162) 0.00388 (0.00364–0.00414) 0.0320 (0.0245–0.0417)
Values shown are micromolar IC50 values (95% Confidence Intervals).
doi:10.1371/journal.pntd.0000190.t002
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Figure 6. Structure based sequence alighnment of DHFR-TS and stereo view of DHFR/NADPH/WR99210 complex inhibitor binding
site. A. A structure based sequence alignment of the DHFR-TS enzymes from P. falciparum (P. fal), P. gallinaceum (P. gal), A. thaliana (A. tha),
Medicago truncatula (M. tru), Theileria annulata (T. ann) and T. gondii (T. gon). The sequence numbering for the P. falciparum and T. gondii is given
above and below the alignment, respectively. The secondary structure elements for P. falciparum DHFR-TS are given above the alignment with blue
cylinders and red arrows representing a-helices and b-sheets, respectively. Residues which display sequence conservation across all species are
highlighted by a black box with reverse type. Those residues which are involved in binding NADPH, pyrimethamine and WR99210 are highlighted by
a red, blue and green box below the alignment, respectively, with those residues which bind both inhibitors and/or NADPH displayed with multiple
colored boxes. B. A stereo view of the P. falciparum DHFR/NADPH/WR99210 complex inhibitor binding site with the closely related inhibitor JPC-
2067-B modeled. Those residues which form close interactions with the inhibitor are labeled and shown in a stick format, colored yellow, red, blue
and orange for carbon, oxygen, nitrogen and sulfur, respectively. The modeled JPC-2067-B inhibitor and NADPH cofactor are colored purple, blue,
red, orange, cyan and green for carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, respectively. In addition His27, in T. gondii DHFR, which
replaces Cys50 in P. falciparum DHFR, is also shown in a stick format (colored orange for carbon and blue for nitrogen) to demonstrate its close
proximity to the modeled JPC-2067-B inhibitor.
doi:10.1371/journal.pntd.0000190.g006
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poorly absorbed and is locally toxic. In addition, WR99210 and its
biguanide PS-15 possess a 2,4,5-trichlorophenoxy structural
feature, which is synthesized from 2,4,5-trichloro-phenol. This
phenol has the potential to generate the highly regulated toxin,
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). This issue precluded
the development of both WR99210 as well as its prodrug PS-15.
Significantly, JPC-2056 and its active metabolite JPC-2067-B are
devoid of this liability and as such offer a significant advance in this
therapeutic class (Table 4). Finally, the LD50 value for JPC-2056
at high doses in the Thompson Antimalarial Assay provides
sufficient therapeutic index to justify continued clinical develop-
ment.
Improved, simpler to use, less toxic drugs that are easily
affordable, which can be prepared in stable solution, are needed to
treat toxoplasmosis. This new biguanide, moving into clinical
trials, promises to be a major advance for the treatment of those
with all forms of toxoplasmosis throughout the world. The
development of JPC-2056 addresses factors limiting use of current
medicines in the developing world for this neglected tropical
disease including ease of administration, lack of toxicity, ease of
monitoring, the potential for low cost, pediatric and parenteral
formulations of a new and improved medicine. This therapeutic is
likely to be of special benefit for those with this neglected tropical
disease in developing countries.
JPC-2067-B and JPC-2056 have considerable promise as a new
class of anti-folate medicines to provide improved and less toxic
means to treat toxoplasmosis as well as malaria caused by P. falciparum
and P.vivax and thus to become a new standard of care for treating
these diseases. The potential of these compounds to act in the absence
of sulfadiazine or in conjunction with other anti-microbials such as
atovaquone presents the possibility of increasing tolerance and
decreasing detrimental side effects including hypersensitivity.
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Table 3. Parasites from Brazil, Guyana, Guatemala, Canada, China and Sri Lanka that were sources of DHFR analyzed.
Isolate Country Source SAG2 Reference: author(date), Reference number
TgCkGa1 Guatemala Chicken2 III,nd Dubey et al. (2005) [50]
TgCkBr125 Brazil Chicken30 III,nd Dubey et al. (2006) [49]
TgCtPRC7 China Cat21 II,nc Dubey et al. (2007a) [48]
TgCkGy2 Guyana Chicken4 III,nc Dubey et al. (2007b) [46]
TgRcCa2 Canada Raccoon3 II,nc Dubey et al. (2008) [45]
TgDgSl12 SriLanka Dog31 II,nc Dubey et al. (2007c) [47]
nc = non clonal, 10 markers were used and data are in references numbers; the 10 nuclear markers include SAG1, SAG2, SAG3, BTUB, GRA6, c22-8, c29-2, L358, PK1 and a
new SAG2, and an apicoplast marker Apico.
nd =only SAGII data.
doi:10.1371/journal.pntd.0000190.t003
Table 4. Structural and Therapeutic Comparisons of JPC-2067, JPC-2056, WR99210 and PS-15.
JPC-2067 JPC-2056 WR99210
Structural Class Dihydrotriazine Biguanide Dihydrotriazine
Manufacturing Liabilities No No Yes
TEST SYSTEM TOXICOLOGICAL FINDINGS
1Ames w/o Activation Not Active* Not Active* Not Active#
1Ames with Activation Not Active* Not Active* Not Active#
1CD-1 Mice Inhibition of Weight Gain at 98 mg/kg for 42 days
1Cynomolgous Monkey Intermittent Loose Stools/Diarrhea 15 mg/kg for 42 days
4Oral LD50 Rat 1,980 mg/kg
4Oral LD50 Mouse 3,510 mg/kg
1Thompson Assay LD50 256 mg/kg @ Day 6 .128 mg/kg @ Day 6
*Tester Strains TA97, TA98, TA100, TA102 and TA1535.
#Tester Strains TA98, TA100, TA1535, TA1537 and TA1538.
doi:10.1371/journal.pntd.0000190.t004
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